Is it safe for an adult with mild renal insufficiency (estimated glomerular filtration rate 60–90 mL/min/1.73 m²) to consume creatine?

Creatine Supplementation in Mild Renal Insufficiency

Creatine supplementation should be avoided in patients with mild renal insufficiency (eGFR 60-90 mL/min/1.73 m²), as there is no guideline support for its use in any stage of chronic kidney disease, and the available research evidence shows it elevates serum creatinine levels without clear benefit in this population.

Evidence-Based Rationale

Guideline Perspective

The KDOQI and international CKD guidelines 1, 2, 3 provide comprehensive recommendations for medication management in patients with reduced kidney function but do not address creatine supplementation at all. This absence is notable—if creatine were considered safe or beneficial in CKD, it would likely appear in nutritional guidance sections. The KDOQI nutrition guidelines 4 focus on protein intake, body composition assessment, and nutritional status but make no mention of creatine supplementation as a therapeutic intervention.

The guidelines consistently emphasize caution with renally excreted substances in patients with eGFR <60 mL/min/1.73 m² 1, 2. While your patient has mild renal insufficiency (eGFR 60-90), this still represents CKD Stage 2, where kidney function is already compromised and warrants careful consideration of any supplement that affects creatinine metabolism.

Research Evidence on Safety

The most recent and comprehensive meta-analysis 5 from 2025 examined 21 studies and found that creatine supplementation causes a statistically significant increase in serum creatinine (MD: 0.07 µmol/L; 95% CI: 0.01 to 0.12; p = 0.03). Importantly, this effect was most pronounced in studies with follow-up >12 weeks, suggesting cumulative effects with chronic use.

A 2026 meta-analysis 6 of 26 studies (1,036 participants) confirmed these findings with even more concerning results:

• Significant increase in serum creatinine (MD: 0.14 mg/dL; 95% CI 0.05-0.22; p = 0.002)
• Reduction in creatinine-based eGFR (MD: -10.75 mL/min; 95% CI -17.48 to -4.02; p = 0.002)

While these studies argue the creatinine elevation reflects altered metabolism rather than true kidney injury (since Cr-EDTA measurements showed no change), this distinction is clinically problematic in your patient with existing mild renal insufficiency.

Critical Clinical Concerns

The fundamental problem: In a patient with eGFR 60-90 mL/min/1.73 m², creatine supplementation will:

1. Artificially elevate serum creatinine, making it impossible to accurately monitor true kidney function progression
2. Lower calculated eGFR by 10-15 mL/min based on the meta-analysis data 6
3. Obscure detection of actual kidney disease progression, which is the primary concern in CKD Stage 2

Even if the creatinine elevation is "metabolic" rather than representing true GFR decline, you lose the ability to use your most accessible and cost-effective monitoring tool (serum creatinine) to track disease progression.

Expert Recommendations from Research

The 2011 safety review 7 explicitly states: "High-dose (>3-5 g/day) creatine supplementation should not be used by individuals with pre-existing renal disease or those with a potential risk for renal dysfunction (diabetes, hypertension, reduced glomerular filtration rate)."

The 2019 Chilean review 8 concludes: "Creatine supplements should not be used in people with chronic renal disease."

The 2026 narrative review 9, while exploring potential benefits of creatine in CKD, acknowledges that "concerns persist about the renal safety of creatine supplementation, especially in individuals with impaired kidney function" and calls for more research before recommending its use.

Practical Clinical Algorithm

For patients with eGFR 60-90 mL/min/1.73 m²:

1. Do not recommend creatine supplementation

2. If patient is already taking creatine:

   • Discontinue immediately
   • Recheck serum creatinine and eGFR 2-4 weeks after discontinuation to establish true baseline
   • Resume standard CKD monitoring protocols

3. If patient insists on supplementation despite counseling:

   • Document informed refusal
   • Consider alternative GFR measurement (cystatin C-based equation or direct measurement) for monitoring
   • Increase monitoring frequency
   • Emphasize this is against medical advice

Common Pitfalls to Avoid

• Don't assume elevated creatinine is "just metabolic" in someone with existing CKD—you cannot distinguish true progression from supplement effect
• Don't rely on the argument that "healthy people tolerate it fine"—your patient has CKD Stage 2, not normal kidneys
• Don't use creatinine-based eGFR for monitoring if patient continues creatine against advice; switch to cystatin C-based equations 10

The risk-benefit analysis clearly favors avoidance: creatine offers no proven therapeutic benefit for CKD patients, while it definitively impairs your ability to monitor disease progression using standard clinical tools.